Welcome to the Division of Pulmonary, Allergy & Critical Care Medicine
The Division of Pulmonary, Allergy and Critical Care Medicine (PACCM) is comprised of a team of outstanding clinicians, scientists, and scholars dedicated to improving the lives of patients with serious lung disease and optimizing the treatment of the critically ill. Read more
About our Fellowship Program
Welcome to the Stanford Pulmonary, Allergy and Critical Care Medicine Fellowship. We offer a 3-year ACGME accredited fellowship designed to provide outstanding clinical and research training in an intellectually vibrant and highly supportive learning environment. Our fellowship’s four distinct tracks are structured to offer trainees experiences that align with their unique career goals. We also offer an additional 4th year of subspecialty training in Lung Transplantation, Pulmonary Hypertension and Sleep Medicine which fellows can apply for in their third year.
All fellows receive 18-20 months of clinical training in Pulmonary & Critical Care Medicine with core rotations at Stanford University Hospital, the Santa Clara Valley Medical Center, and the Palo Alto VA Health Care System. By rotating at these hospitals with distinct patient populations, fellows are exposed to a wide breadth of disease states and pathology. Our elective courses provide the opportunity for the additional in-depth study of specific areas of interest. Our fellows are also provided ample time to explore outstanding research opportunities at Stanford. Thank you for your interest in our fellowship program and for exploring our website. Please don't hesitate to contact us for further information. We are currently recruiting fellows for the class of 2019, as part of the NRMP match.
Events and Announcements
October 14, 2019
Early Monday morning, the 2019 Nobel Prize in Physiology or Medicine was awarded to three scientists who discovered how cells detect and respond to changes in oxygen levels.
There's a nice Stanford link to this prize: New Nobel laureate Gregg Semenza, MD, PhD, of the Johns Hopkins University School of Medicine, is collaborating with Stanford's Mark Nicolls, MD, on a way to use Semenza's prizewinning discovery to help lung transplant recipients.
"I was up at 5:30 a.m. emailing and congratulating Gregg," said Nicolls, describing his reaction to the Nobel Prize announcement. "I was absolutely thrilled. It was well deserved."
Lung transplants do not last as long as other solid-organ transplants, with only about half of recipients alive after five years. But a piece of research that evolved from the Nobel Prize discovery may help to change that.
Semenza's portion of the award recognized the discovery of HIF-1 alpha, a protein that switches genes on and off in response to low oxygen levels. This protein and its sister molecule, HIF-2 alpha, play important roles in maintaining the health of blood vessels. Loss of healthy blood vessels is a big contributor to failure of lung transplants.
Starting in 2011, Nicolls, a pulmonologist, and his Stanford team began publishing research with Semenza in which they increased HIF-1 alpha and HIF-2 alpha levels in animal models of lung transplant. When these proteins were more plentiful, the transplanted organs were healthier and lasted longer.
From that work, they've devised and patented a medication to turn up HIF-1 alpha levels. "It's a fluid that surgeons will apply to the transplanted lungs at the time of the operation to enhance natural blood vessel repair," Nicolls said. The treatment is in the process of being brought to market.
Nicolls and Semenza are figuring out how to apply the same principles to chronic lung transplant rejection.
"Lung transplant rejection is like a heart attack of the airways: You lose blood supply and get a scar, which turns into chronic rejection," Nicolls said, adding that chronic rejection is the No. 1 killer of lung transplant recipients. But turning up the HIF proteins can slow or reverse the process.
Semenza has been an important mentor and collaborator, Nicolls said, adding "He's a very generous but very careful and rigorous scientist."
And their findings illustrate the value of basic science, driven by curiosity rather than a particular goal. When Semenza first discovered HIF-1 alpha, he could not have guessed that the work might someday lead to longer-lasting lung transplants.
"When you learn how cells operate, the lessons can have very broad implications that only become apparent as years and decades go by," Nicolls said.
September 26, 2019
It's a real pleasure to announce a major NIH award to Joe Levitt, our talented ICU faculty member and Program Director for the PCCM Fellowship.
He will be leading the NIH/NHLBI ARREST Pneumonia Study, a 10-center, 600-patient clinical trial to validate the efficacy of inhaled corticosteroids and beta agonists for the prevention of lung injury and acute respiratory failure in patients hospitalized with pneumonia and hypoxemia.
This trial is a follow-up to the 60-patient trial published in Critical Care Medicine as part of Joe’s previous K23 Award. If successful, this trial has the potential to change management and improve outcomes of patients hospitalized with pneumonia, the leading infectious cause of hospitalization and death in the U.S.
The $7.7M award is a collaborative effort with Manisha Desai (Director of the Stanford Qualitative Science Unit which will serve as the data coordinating center) and Ken Mahaffey (Director of the Stanford Center for Clinical Research which will serve as the clinical coordinating center). Supporting this type of collaborative and impactful clinical research is precisely the mission of these important entities at Stanford.
With Angela Rogers (Associate Program Director for PCCM Fellowship and Internal Medicine Residency) and our peers in Anesthesia, Surgery, CV Surgery, Neurology and Emergency Medicine, Joe is helping, with this award, to build a prominent critical care research national presence at Stanford University.
September 24, 2019
Today, we learned that the request to change the division's name was approved by the School of Medicine.
The Division's name has been changed from ‘Pulmonary & Critical Care Medicine’ to ‘Pulmonary, Allergy & Critical Care Medicine’ and has been approved effective September 1, 2019.
This name change reflects several years of program building initiated by Dr. Kari Nadeau's transformative arrival to our Division, the establishment of the Sean N. Parker Center for Allergy and Asthma Research under Kari's leadership, and the recent opening of the Allergy, Asthma & Immunodeficiency Clinic in Atherton; the latter effort made possible by the tireless efforts of Dr. Chitra Dinakar.
Allergy is a truly interdisciplinary venture. We will work closely with our colleagues in Pediatrics, Immunology & Rheumatology, Otolaryngology Head & Neck Surgery, Infectious Diseases, GI and Cardiology to facilitate collaboration in both clinical care and research projects. We will work shoulder-to-shoulder with our friends in other divisions and departments.
September 16, 2019
Stanford Adult Allergy, Immunodeficiency and Asthma Clinic opens in Atherton Monday, September 16th, 2019.
We are proud to announce that the opening of the first free-standing Adult Allergy Clinic for Stanford University.
Working under the guidance of Dr. Chitra Dinakar, Clinical Chief of Allergy and the strong support of Stanford Health Care, Drs. Priscilla Wong and Anna Arroyo (our founding faculty for the clinic) have been working hard every day to prepare the clinic for its opening.
This initiative has its roots in Dr. Kari Nadeau coming into the the PCCM division several years ago.
Under Dr. Nadeau, the Sean N. Parker Center for Allergy and Asthma Research has performed transformative research in the field of food allergy.
PCCM will work collaboratively with our colleagues in Pediatrics, Rheumatology, and ENT to provide state-of-the-art care for patients suffering from allergy, immunodeficiency and asthma.
This clinic will also be a site for Allergy Fellow training.
A warm congratulations to the whole Allergy team - you all have worked spectacularly together over the last year to make this dream a reality, and the community will be your greatest beneficiaries.
September 13, 2019
Stanford's Medicine X program is advertised to be the 'world's leading program in health care innovation, patient engagement and emerging technologies.'
This year the conference focuses on solving the issue of curing and treating COPD and is being led by news celebrity Ted Koppel and Grace Anne Dorney Koppel (a COPD patient/advocate). Ted and Grace Anne are dedicated Stanford alumni. The event will be live-streamed. We are honored to have our faculty participating to represent Stanford as well as Divisional initiatives to tackle COPD care in the Bay Area.
'Stanford Medicine X is a multifaceted program that represents a new way of solving health care’s most pressing problems. Sown in the fertile soil of Stanford University’s rich academic resources; germinated at the grassroots level by passionate, imaginative people; nurtured in the high-energy, risk-taking environment of Silicon Valley, Medicine X is an innovative way of re-imagining digital health, medical education, clinical research, new health care venture formation, and more.'
Its attendees are designers, philanthropists and innovators looking for ways to creatively tackle society's unmet medical problems.
August 31, 2019
We are excited to report the official accreditation of The Stanford Hereditary Hemorrhagic Telangiectasia (HHT) Program as a Center of Excellence by the Cure HHT Foundation! Edda Spiekerkoetter will be the center director, and David Stevenson from LPCH Medical Genetics will be the associate director. The center will be administered and supported by the adult PCCM pulmonary vascular disease program. Over two years ago, Edda and David began the process of creating a multidisciplinary program which includes collaboration with medical genetics, interventional radiology, neurosurgery, ENT surgery, and support from hospital administration. In accrediting the program as a center of excellence, the Cure Foundation cited not only excellence in clinical care but specifically the existing research expertise of Stanford University as a major strength. Congrats to Edda and David!
June 18, 2019
Congratulations to Dr. Angela Rogers, winner of the 2019 McCormick Fellowship Award. This award was established to support the advancement of women in medicine and/or medical research directly, or by supporting the mentoring, training and encouragement of women pursuing the study of medicine, in teaching medicine, and engaging in medical research.
To all of you who work with and have been taught by Angela, you know how much she has contributed to our group since her arrival from Harvard a few years ago. As the Associate Director of the PCCM Fellowship and the Associate Program Director of the Department of Medicine Residency, she has had a truly transformative effect on the Division and Department while still managing to be a great intensivist and clinical researcher, a true role model.
May 31, 2019
We are pleased to announce that Dr. Joshua Mooney will be the new Associate Medical Director for Lung and Heart/Lung Transplantation at Stanford. Josh is a well-respected and thoughtful clinician who has made a significant contribution to our program as well as to the field. He has led a number of academic efforts to improve the allocation of organs to patients with advanced lung disease. He is beloved by his peers, patients, trainees and staff alike.
We have an incredibly busy and complex lung transplant program at Stanford. In addition to providing leadership help to Dr. Gundeep Dhillon (Medical Director), Josh will be guiding important quality initiatives in close coordination with SHC.
May 28, 2019
Congratulations to Lauren Eggert for her ATS Poster presentation, titled “Physicians May Be More Frequently Switching Biologics In Patients With Severe Asthma Who Have Problems With Initial Treatment, Research Indicate”, which made the ATS Morning Minute.
May 2, 2019
Dr. Mark Krasnow, the Executive Director of the Wall Center for Pulmonary Vascular Disease, has been recognized with one of the world's most distinguished honors, election into the National Academy of Sciences. The academy was created in 1863 to advise the nation on issues related to science and technology with scholars being elected after outstanding contributions to research. 2019 was a banner year for Stanford with four new members from the school of medicine being elected.
Mark , a Howard Hughes Medical Institute investigator, has trained a number of scientists who are now in prominent academic positions around the country. He uses genetic and genomic approaches to examine lung development and stem cells and the neural circuit of breathing. He has been an extremely effective leader of the Wall Center and has helped raise the national stature of our pulmonary programs. We are all super proud of Mark's latest recognition and are grateful for his ongoing leadership at the medical school.
April 26, 2019
Huge congrats to Paul Mohabir for again winning the The Arthur L. Bloomfield Award in Recognition of Excellence in the Teaching of Clinical Medicine! This award was established in recognition of Dr. Arthur L. Bloomfield’s reputation as a gifted teacher, and eligible recipients are individuals from the Stanford faculty who excel as teachers in clinical medicine. The Award recipients are recognized at the School of Medicine Commencement Ceremony. Dr. Mohabir has been recipient of numerous teaching awards including the Kaiser award which recognizes pre-clinical teaching.
April 26, 2019
A big congratulations to Nick Juul for his new NIH F32 award on lung aging and cancer! Nick is doing a great job under Tushar Desai's mentorship.
Well done, Nick!
April 22, 2019
A big congratulations to Professor Chitra Dinakar, Clinical Chief of Allergy at Stanford, for winning the American Academy of Pediatrics 2019 Jerome Glaser Award!
This award recognizes one outstanding pediatric allergist-immunologist in the nation for contributions in service, education, and as a clinician/teacher in Allergy and Immunology - a huge honor!
February 27, 2019
"Edda Spiekerkoetter, a pulmonary hypertension clinician-scientist, is the recipient of a new Department of Defense (DOD) grant addressing hereditary hemorrhagic telangiectasia (HHT), a condition associated with significant pulmonary vascular disease. This is a joint study with Dr. Spiekerkoetter serving as the principal investigator and Ross Metzger (Pediatric Cardiology), Astrid Gillich (Biochemistry) and David Stevenson (Medical Genetics), as co-investigators. Edda and colleagues are establishing a HHT Center of Excellence at Stanford, and this grant will be instrumental in supporting the basic research as well as clinical translational approaches for the new Center. Congratulations Edda and team!"
February 4, 2019
Dr. Ramon Ramirez III was awarded the best clinical abstract award at the 13th PVRI Annual World Congress on Pulmonary Vascular Disease in Barcelona, Spain. This meeting is the largest scientific meeting on the subject of pulmonary vascular diseases. Of a total of 300 abstracts, Ramon's work on prescription-based stimulants and risk of PAH was chosen to compete as an oral presentation and judged by key opinion leaders in the field. A big congrats to Ramon!
January 31, 2019
Congratulations to three new high impact publications in the Division!
Andrew Sweatt and colleagues published an exciting study using machine learning to classify patients with pulmonary arterial hypertension.1
Xinguo Jiang et al discovered a new survival molecule for airway blood vessels.2
Ke Yuan and co-authors evaluated pericyte changes in pulmonary arterial hypertension.3
1.Sweatt, A. J., Hedlin, H. K., Balasubramanian, V., Hsi, A., Blum, L. K., Robinson, W. H., Haddad, F., Hickey, P. M., Condliffe, R. A., Lawrie, A., Nicolls, M. R., Rabinovitch, M., Khatri, P., Zamanian, R. T. Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension. Circ Res 2019 Jan 21. doi: 10.1161/CIRCRESAHA.118.313911
2. Jiang, X., Tian, W., Tu, A. B., Pasupneti, S., Shuffle, E., Dahms, P., Zhang, P., Cai, H., Dinh, T. T., Liu, B., Cain, C., Giaccia, A. J., Butcher, E. C., Simon, C., Semenza, G. L., Nicolls, M. R.Endothelial HIF-2alpha is Required for the Maintenance of Airway Microvasculature. Circulation 2019 Jan 22;139(4):502-517.
3. Yuan K, Shamskhou EA, Orcholski ME, Nathan A, Reddy S, Honda H, Mani V, Zeng Y, Ozen MO, Wang L, Demirci U, Tian W, Nicolls MR, de Jesus Perez VA.Loss of Endothelial Derived WNT5A is Associated with Reduced Pericyte Recruitment and Small Vessel Loss in Pulmonary Arterial Hypertension. Circulation 2018 Dec 11. doi: 10.1161/CIRCULATIONAHA.118.037642
January 30, 2019
Congratulations to Dr. Mark Nicolls and Amy Tian for being awarded a new $2.3M NIH R01 grant evaluating the role of inflammation in lymphedema. Together with Dr. Stan Rockson, the Nicolls' group recently published a study in the journal JCI Insight (October 2018) showing the effectiveness of anti-inflammatory therapy (ketoprofen) for this disease. Lymphedema is a chronic condition affecting hundreds of millions around the world. It is particularly troublesome to patients who have had lymph node resection for breast cancer and is caused by lymphatic obstruction which leads to disfigured and swollen extremities. Targeted anti-inflammatory therapy is a promising new approach for this disorder.
See our Grand Rounds, Core Lectures, Conferences, and more.